全球癌症免疫療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計癌症免疫療法市場將從 2025 年的 1,161.3 億美元成長到 2034 年的 4,361.8 億美元，2026 年至 2034 年的複合年成長率為 15.84%。

隨著創新治療方法不斷革新癌症治療，全球癌症免疫療法市場正經歷快速成長。免疫療法利用人體自身的免疫系統來靶向並摧毀癌細胞，與傳統治療方法相比，有望提高生存率並減少副作用。全球癌症發生率的上升以及人們對先進治療方法的認知不斷提高，是成長要素。

對研發的大量投入正在加速新型治療方法的問世，例如查核點抑制劑、CAR-T細胞療法和單株抗體。製藥公司正與研究機構合作開發個人化治療方案。新型免疫療法的監管核准也促進了其在關鍵醫療保健市場的擴張。

隨著精準醫療和基於生物標記的治療方法日益普及，未來前景十分光明。技術進步和不斷擴大的臨床試驗有望擴大多種癌症類型的治療應用範圍。醫療保健支出的成長和政府的支持將在未來幾年推動全球癌症免疫療法市場的持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球癌症免疫療法市場：依產品類型分類

• 市場分析、洞察與預測
• 查核點抑制劑
• 單株抗體
• 疫苗
• 細胞療法
• 免疫調節劑
• 溶瘤病毒

第5章 全球癌症免疫療法市場：依應用領域分類

• 市場分析、洞察與預測
• 肺癌
• 乳癌
• 黑色素瘤
• 多發性骨髓瘤
• 攝護腺癌
• 卵巢癌
• 子宮頸癌
• 胃癌
• 結腸癌
• 頭頸癌
• 其他

第6章 全球癌症免疫療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 腫瘤診所
• 居家照護
• 其他

第7章：全球癌症免疫療法市場：依形式分類

• 市場分析、洞察與預測
• 靜脈注射（IV）
• 肌肉內部
• 口服

第8章 全球癌症免疫療法市場：按分銷管道分類

• 市場分析、洞察與預測
• 直接競標
• 零售銷售
• 藥局

第9章 全球癌症免疫療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck & Co. Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceutical
  • AstraZeneca
  • Gilead Sciences Inc
  • Lilly
  • Amgen Inc
  • Novartis AG
  • GSK Plc
  • Pfizer Inc
  • AbbVie Inc
  • Bayer AG
  • BioNTech SE
  • Moderna Inc

The Cancer Immunotherapy Market size is expected to reach USD 436.18 Billion in 2034 from USD 116.13 Billion (2025) growing at a CAGR of 15.84% during 2026-2034.

The Global Cancer Immunotherapy Market is experiencing rapid growth as innovative treatments transform cancer care. Immunotherapy harnesses the body's immune system to target and destroy cancer cells, offering improved survival rates and fewer side effects compared to traditional therapies. Rising cancer prevalence worldwide and increasing awareness about advanced treatment options are key growth drivers for the market.

Significant investments in research and development are accelerating the introduction of novel therapies such as checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies. Pharmaceutical companies are collaborating with research institutions to develop personalized treatment approaches. Regulatory approvals for new immunotherapy drugs are also contributing to expanding market availability across major healthcare markets.

Future prospects remain highly promising as precision medicine and biomarker-based therapies gain traction. Technological advancements and expanding clinical trials are expected to broaden treatment applications across multiple cancer types. Growing healthcare expenditure and supportive government initiatives will likely continue driving the global cancer immunotherapy market toward sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

By Application

• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

By End User

• Hospitals
• Oncology Clinics
• Homecare
• Others

By Form

• Intravenous (IV)
• Intramuscular
• Oral

By Distribution Channel

• Direct Tenders
• Retail Sales
• Pharmacies

COMPANIES PROFILED

• Merck Co Inc, F HoffmannLa Roche Ltd, BristolMyers Squibb Company, Janssen Pharmaceutical, AstraZeneca, Gilead Sciences Inc, Lilly, Amgen Inc, Novartis AG, GSK plc, Pfizer Inc, AbbVie Inc, Bayer AG, BioNTech SE, Moderna Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Oncolytic Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Head & Neck Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Form
• 7.2. Intravenous (IV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Direct Tenders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Application
  • 9.2.3 By End User
  • 9.2.4 By Form
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Application
  • 9.3.3 By End User
  • 9.3.4 By Form
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Application
  • 9.4.3 By End User
  • 9.4.4 By Form
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Application
  • 9.5.3 By End User
  • 9.5.4 By Form
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Application
  • 9.6.3 By End User
  • 9.6.4 By Form
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co. Inc
  • 11.2.2 F. Hoffmann-La Roche Ltd
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 Janssen Pharmaceutical
  • 11.2.5 AstraZeneca
  • 11.2.6 Gilead Sciences Inc
  • 11.2.7 Lilly
  • 11.2.8 Amgen Inc
  • 11.2.9 Novartis AG
  • 11.2.10 GSK Plc
  • 11.2.11 Pfizer Inc
  • 11.2.12 AbbVie Inc
  • 11.2.13 Bayer AG
  • 11.2.14 BioNTech SE
  • 11.2.15 Moderna Inc